[The clinical outcome of minilaparotomy approach for curative resection of stage 0 and I XXXX ].

@entity1 @entity190 @entity5 @entity3 @entity694
Since July 2000, we have been performing minilaparotomy as a minimally invasive alternative to laparoscopic surgery for @entity694 , and we reported the technique and short-term oncological results. In the present study, the clinical outcomes of minilaparotomy approach for curative resection of stage 0 and I @entity694 were evaluated. One hundred twenty-seven @entity1 underwent curative resection of stage 0 and I @entity694 via minilaparotomy (skin incision, >= 7 cm) between July 2000 and March 2009. Of the 127 @entity1 , 17 @entity1 underwent an additional resection after EMR. There were 84 @entity1 and 43 @entity1 with a median age of 67 years. Their median body mass index was 22.6 kg/m2. ASA stage was stage I in 100, stage II in 12, and stage III in 15. Thirty-nine cases had received a prior abdominal surgery. The median operation time was 110 min and median @entity190 was 50 mL. The D1, D2 and D3 lymph node dissection was performed in 37, 63 and 27 cases, respectively. The minilaparotomy approach was successfully performed in 120 out of 127 @entity1 . Three of 7 cases failed to affect the adhesion caused by prior abdominal surgery. The ratio of 5-year overall survival rate was 95%, and two cases of stage I had developed a @entity5 recurrence ( @entity3 to liver and para-aortic lymph nodes), one @entity1 died of para-aortic lymph nodes recurrence. A minilaparotomy approach to the curative resection for @entity694 is feasible and safe, and would be oncologically an adequate procedure.
